Last reviewed · How we verify
NCT03374592
Volumetric Intensity Modulated Arc Therapy vs. Conventional Radiotherapy for Cancer Pain
NA trial testing Volumetric Intensity-Modulated Arc Therapy in Neoplasm Metastasis in 73 participants. Completed in 21 February 2018.
20 December 2017
Quick facts
| Lead sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 73 |
| Start date | 7 July 2014 |
| Primary completion | 20 December 2017 |
| Estimated completion | 21 February 2018 |
Drugs / interventions tested
- Volumetric Intensity-Modulated Arc Therapy
- Conventional Radiotherapy
Conditions studied
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
- Pain — all drugs for Pain →
- Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
- Quality of Life — all drugs for Quality of Life →
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Who can join
Eligibility, any sex, with Neoplasm Metastasis or Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study compares the use of conventional radiotherapy technique with volumetric intensity-modulated radiotherapy (VMAT) in the treatment of painful cancer metastases. Half of the patients will receive radiotherapy using a conventional technique, while the other half will receive their treatment using a the VMAT technique.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03374592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasm Metastasis
Currently open trials in the same condition.
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06534580 — Virtual Reality for Advanced Cancer Pain · active not recruiting
- NCT06460961 — A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-68 · Phase 1 · active not recruiting
- NCT05573893 — PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat · recruiting
- NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting
Other Centre hospitalier de l'Université de Montréal (CHUM) trials
Trials by the same sponsor.
- NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
- NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
- NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
- NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
- NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03374592 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
- Last refreshed: 16 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03374592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing